UK markets closed
NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.87 -0.76 (-0.92%) GOLD FUTURES
2,305.60 -52.10 (-2.21%) DOW
37,977.06 -409.03 (-1.07%) Bitcoin GBP
50,119.69 -539.11 (-1.06%)
NVO Jan 2025 140.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:59AM EDT. Market open.
| Previous close | 10.85 |
| Open | 11.00 |
| Bid | 11.20 |
| Ask | 11.50 |
| Strike | 140.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.00 - 12.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.31k |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
ZacksEli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
© 2024 Yahoo. All rights reserved.